Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$770.00 USD

770.00
1,669,052

-1.12 (-0.15%)

Updated May 17, 2024 04:00 PM ET

After-Market: $770.30 +0.30 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (190 out of 249)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays

We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.

    Arpita Dutt headshot

    How Incyte Stock Became a Bull Market Star for Biotech Investors

    Incyte (INCY) tops the list of stocks that enjoyed a stupendous run in the last 8 years.

      Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA

      Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.

        Sweta Killa headshot

        Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs

        President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.

          Eli Lilly's Taltz Shows Better Efficacy than J&J's Stelara

          Eli Lilly and Company (LLY) announced superior efficacy in a head-to-head study evaluating its marketed drug, Taltz (ixekizumab) versus with Johnson & Johnson???s Stelara (ustekinumab) in patients with moderate-to-severe plaque.

            Merrimack (MACK): What Awaits the Stock in Q4 Earnings?

            Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.

              Arpita Dutt headshot

              Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ

              The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.

                What's Driving Lilly's (LLY) Shares after 2016 Decline?

                After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.

                  The Zacks Analyst Blog Highlights: Berkshire Hathaway, Eli Lilly, T-Mobile, Oracle and Marathon Petroleum

                  The Zacks Analyst Blog Highlights: Berkshire Hathaway, Eli Lilly, T-Mobile, Oracle and Marathon Petroleum

                    Arpita Dutt headshot

                    Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback

                    Merck's (MRK) news represents the latest setback in the pharma and biotech sector's quest to find a treatment for Alzheimer's.

                      Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook

                      Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.

                        Merck (MRK) Halts Late Stage Alzheimer Study; Shares Slip

                        Merck & Co., Inc. (MRK) announced that it is discontinuing a late-stage study evaluating its pipeline candidate, verubecestat for the treatment of mild-to-moderate Alzheimer's disease due to lack of efficacy.

                          Lilly's Olumiant Gets Marketing Authorization in Europe

                          Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.

                            Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

                            The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.

                              Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.

                              Amgen Inc. (AMGN) announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

                                GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1

                                GW Pharmaceuticals plc (GWPH) reported first-quarter fiscal 2017 loss of 77 cents per share, much narrower than both the Zacks Consensus Estimate of a loss of $1.35 and the year-ago figure of 82 cents.

                                  ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib

                                  ARIAD Pharmaceuticals, Inc. (ARIA) announced the submission of a Marketing Authorisation Application (MAA) for its experimental ALK inhibitor, brigatinib, with the European Medicines Agency (EMA).

                                    Auris (EARS) Expands Pipeline with Intranasal Betahistine

                                    Auris (EARS) announced that it has strengthened its pipeline by the addition of AM-125 as the third clinical-stage program, which allowed it to expand into the field of vestibular disorders.

                                      Sweta Killa headshot

                                      Q4 Earnings Faring Well for Pharma ETFs

                                      Despite the fact that the industry primes posted mixed results, the stocks witnessed smooth trading following their results.

                                        Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More

                                        Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season.

                                          Bristol-Myers' Injectable Opdivo Gets FDA Approval for mUC

                                          Bristol-Myers Squibb Company (BMY) announced that the FDA has approved an injectable form of immuno-oncology drug Opdivo

                                            The Zacks Analyst Blog Highlights: Eli Lilly, Aetna, Automatic Data Processing, Dollar General and Sprint

                                            The Zacks Analyst Blog Highlights: Eli Lilly, Aetna, Automatic Data Processing, Dollar General and Sprint

                                              AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales

                                              AstraZeneca PLC (AZN) reported fourth-quarter 2016 core earnings of $1.21 per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 51 cents. Core earnings also rose 9% year over year.

                                                Merck (MRK) Tops Q4 Earnings; Pharmaceutical Sales Down

                                                Merck & Co., Inc. (MRK) reported fourth-quarter 2016 earnings of 89 cents per share, which beat the Zacks Consensus Estimate of 88 cents by a penny.

                                                  Sheraz Mian headshot

                                                  Q4 Scorecard and Analyst Reports for Eli Lilly, ADP & Aetna

                                                  Today's Research Daily features new research reports on 16 major stocks and a real-time update on the Q4 earnings season.